WHO Prequalifies Three-Dose Maternal RSV Vaccine Presentation
The World Health Organization has prequalified a three-dose presentation of Pfizer’s maternal respiratory syncytial virus vaccine, a decision that could make infant protection easier to procure and deliver in lower-income countries.
WHO announced the decision on September 9, 2026. The prequalification applies to RSVpreF, sold as ABRYSVO, and follows the agency’s prequalification of the vaccine’s single-dose presentation in March 2025.
What changed
The WHO prequalified-vaccines registry records the new presentation as a two-vial active-plus-excipient set containing three doses. It lists Pfizer Europe MA EEIG as the manufacturer and the European Medicines Agency as the responsible regulatory authority. The registry gives August 24, 2026, as the prequalification date.
WHO said the multi-dose format is expected to make maternal RSV vaccination more affordable and easier to deliver, particularly in countries supported by Gavi, the Vaccine Alliance. A three-dose vial may also help programs manage uneven numbers of pregnant patients and reduce the risk of unused doses, although the agency has not announced a universal price reduction.
The decision does not mean the vaccine is already being rolled out worldwide. WHO prequalification is a quality-assurance step that can support procurement through United Nations channels. Countries still must make policy decisions, address financing and supply, complete applicable regulatory steps and connect vaccination with prenatal care.
How the vaccine protects infants
The vaccine is given to pregnant women during the third trimester. WHO recommends administration from week 28 onward to support the transfer of protective antibodies across the placenta before birth.
The aim is to protect babies during their first six months of life, when they are especially vulnerable to severe RSV illness. The maternal vaccine is different from nirsevimab, a long-acting monoclonal antibody administered directly to infants. WHO says countries should introduce either the maternal vaccine or nirsevimab according to feasibility, cost-effectiveness and expected coverage.
Why the format matters
WHO estimates that RSV causes more than 3.6 million hospitalizations and approximately 100,000 deaths each year among children under 5. Nearly half of those deaths occur in infants younger than 6 months, and about 97% occur in low- and middle-income countries, according to the agency.
Gavi said the prequalification strengthens the pathway toward introductions in lower-income countries. Gavi-eligible countries can apply for support, but each introduction still depends on country decision-making, financing, procurement and the ability to deliver vaccination through routine maternal-health services.
The practical significance of the decision is therefore operational rather than immediate. The three-dose presentation removes one packaging and procurement barrier, but it does not by itself resolve cold-chain capacity, staffing, access to prenatal care or sustained financing.
What happens next
Countries and financing partners will determine whether and when to introduce the vaccine. Their decisions will depend on procurement planning, national recommendations, regulatory requirements, available funding and the ability to offer vaccination through routine antenatal services.
WHO’s action creates another route for countries to obtain a prequalified maternal RSV vaccine presentation. Whether that translates into protection for more infants will depend on how effectively health systems turn the new option into sustained coverage among pregnant women.
Sources
- WHO announcement on the multi-dose RSV vaccine vial
- WHO prequalified vaccines registry
- Gavi statement on the multi-dose maternal RSV vaccine
Look for updates to this story
Discover more from Interactive News
Subscribe to get the latest posts sent to your email.